Key result
Polypharmacy linked to ~88% more severe adverse drug events, notably cardiac and renal in older adults.
Why the study?
Older adults have a higher risk of severe adverse drug events due to multimorbidity, polypharmacy, and reduced physiological function, but the specific association with polypharmacy warranted evaluation.
Does polypharmacy increase the risk of severe adverse drug events in older adults compared to younger adults?
Observational (n=793,498)
Does polypharmacy increase the risk of severe adverse drug events in older adults compared to younger adults?
Polypharmacy in older adults is associated with an increased risk of severe adverse drug events, particularly acute cardiac arrest and renal failure, highlighting the need for close monitoring when adding new medications.
Answers are grounded in this paper and cite their sources.
Polypharmacy may heighten severe ADE risk in older adults; leaves open causal effects and deprescribing benefits in prospective studies.
BACKGROUND: Older adults are at a higher risk of severe adverse drug events (ADEs) because of multimorbidity, polypharmacy, and lower physiological function. This study aimed to determine whether polypharmacy, defined as the use of ≥ 5 active drug ingredients, was associated with severe ADEs in this population. METHODS: We used ADE reports from the Korea Institute of Drug Safety and Risk Management-Korea Adverse Event Reporting System Database, a national spontaneous ADE report system, from 2012 to 2021 to examine and compare the strength of association between polypharmacy and severe ADEs in older adults (≥ 65 years) and younger adults (20-64 years) using disproportionality analysis. RESULTS: We found a significant association between severe ADEs of cardiac and renal/urinary Medical Dictionary for Regulatory Activities System Organ Classes (MedDRA SOC) with polypharmacy in older adults. Regarding individual-level ADEs included in these MedDRA SOCs, acute cardiac arrest and renal failure were more significantly associated with polypharmacy in older adults compared with younger adults. CONCLUSION: The addition of new drugs to the regimens of older adults warrants close monitoring of renal and cardiac symptoms.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2024) conducted an observational in Adverse Drug Events (n=793,498). Polypharmacy vs. Non-polypharmacy (< 5 concomitant drugs) was evaluated on Severe adverse drug event reporting (PRR 1.88, 95% CI 1.80-1.96, p=<0.001). Polypharmacy was associated with an increased risk of severe adverse drug events, with older adults showing a particularly strong association for cardiac and renal events.
Synapse has enriched 10 related papers. Consider them for comparative context: